These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29613968)

  • 1. Dosimetry-based treatment for Graves' disease.
    Hyer SL; Pratt B; Gray M; Chittenden S; Du Y; Harmer CL; Flux GD
    Nucl Med Commun; 2018 Jun; 39(6):486-492. PubMed ID: 29613968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
    Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with Graves' disease.
    Markovic V; Eterovic D
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3547-52. PubMed ID: 17609305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
    Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G
    Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
    Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
    Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dosimetric approach to patient-specific radioiodine treatment of Graves' disease with incorporation of treatment-induced changes in thyroid mass.
    Traino AC; Di Martino F; Lazzeri M
    Med Phys; 2004 Jul; 31(7):2121-7. PubMed ID: 15305466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome.
    Catargi B; Leprat F; Guyot M; Valli N; Ducassou D; Tabarin A
    Eur J Endocrinol; 1999 Aug; 141(2):117-21. PubMed ID: 10427153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation.
    Traino AC; Grosso M; Mariani G
    Phys Med; 2010 Apr; 26(2):71-9. PubMed ID: 19800827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review and Meta-Analysis of the Relationship Between the Radiation Absorbed Dose to the Thyroid and Response in Patients Treated with Radioiodine for Graves' Disease.
    Taprogge J; Gape PMD; Carnegie-Peake L; Murray I; Gear JI; Leek F; Hyer SL; Flux GD
    Thyroid; 2021 Dec; 31(12):1829-1838. PubMed ID: 34598656
    [No Abstract]   [Full Text] [Related]  

  • 12. Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass.
    Orsini F; Traino AC; Grosso M; Guidoccio F; Boni G; Volterrani D; Mariani G
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):496-502. PubMed ID: 23358401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximum dose rate is a determinant of hypothyroidism after 131I therapy of Graves' disease but the total thyroid absorbed dose is not.
    Krohn T; Hänscheid H; Müller B; Behrendt FF; Heinzel A; Mottaghy FM; Verburg FA
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4109-15. PubMed ID: 25033065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioiodine (131I) therapy of Graves' disease: use of the new high resolutional ultrasonic scanner for the determination of the accurate weight of the thyroid gland.
    Nagayama Y; Ashizawa K; Matsuo K; Inoue S; Harakawa S; Hirayu H; Yamashita S; Izumi M; Nagataki S
    Endocrinol Jpn; 1989 Jun; 36(3):359-65. PubMed ID: 2684619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcome of 131I treatment in Graves' patients pretreated or not with methimazole.
    Pirnat E; Zaletel K; Gaberšček S; Hojker S
    Hell J Nucl Med; 2011; 14(1):25-9. PubMed ID: 21512661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing the success of radioiodine therapy in patients with Graves' disease.
    Šfiligoj D; Gaberšček S; Mekjavič PJ; Pirnat E; Zaletel K
    Nucl Med Commun; 2015 Jun; 36(6):560-5. PubMed ID: 25714667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves' disease.
    Moura-Neto A; Mosci C; Santos AO; Amorim BJ; de Lima MC; Etchebehere EC; Tambascia MA; Ramos CD; Zantut-Wittmann DE
    Clin Nucl Med; 2012 Jun; 37(6):550-4. PubMed ID: 22614185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graves' disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy?
    Kobe C; Eschner W; Sudbrock F; Weber I; Marx K; Dietlein M; Schicha H
    Nuklearmedizin; 2008; 47(1):13-7. PubMed ID: 18278207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in graves' ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves' disease from 2 prospective, randomized, open-label, blinded end point studies.
    Chen DY; Schneider PF; Zhang XS; Luo XY; He ZM; Chen TH
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):1-6. PubMed ID: 24203649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.